COLL

Collegium is a focused, profitable specialty pharma operating in two structurally different niches. The pain portfolio (Xtampza ER, Belbuca, Nucynta franchise) is a managed-decline/durable-annuity business: branded abuse-deterrent opioids hold defensible patent moats (Xtampza ER generic entry not before September 2033 per Teva settlement; Nucynta ER patents extend to ~2029) but secular opioid prescribing pressure constrains upside, and Nucynta IR faces potential generic entry as early as January 2027. The ADHD pond is different: Jornay PM is a genuine growth asset, and the AZSTARYS acquisition (closed May 12, 2026 for $650M) adds a second growth driver. The combined ADHD revenue run-rate could approach $250-265M in FY2026 in a US ADHD drug market estimated at $18.5-26.6B growing at 5-7% annually — with combined ADHD share still sub-2%, implying substantial organic headroom. The pain portfolio contributed the bulk of FY2025's $780.6M revenue and is funding the ADHD pivot; the structural question is whether ADHD revenues compound fast enough to offset pain franchise secular erosion before the pain annuity meaningfully shrinks. Operating cash flow was $329.3M in FY2025 on $780.6M revenue — a ~42% OCF margin that is exceptional for a company at this size. Post-AZSTARYS, net leverage temporarily rose to approximately 2x net debt/EBITDA — manageable but not negligible at a ~$1.03B market cap.

ADHD platform pivot at 3x operating cash flow — integration and Nucynta cliff are the test

Snapshot

What it does

Collegium Pharmaceutical is a specialty pharma company focused on two segments: branded chronic pain and branded ADHD.

The pain portfolio includes Xtampza ER (extended-release oxycodone with abuse-deterrent technology), Belbuca (buprenorphine buccal film for opioid-naive patients), and the Nucynta franchise (tapentadol IR and ER, acquired from Assertio). These are branded abuse-deterrent opioids — a niche where Collegium holds defensible patent positions and managed-care formulary depth built over years. The pain segment is cash-rich but grows modestly, and is exposed to secular prescribing headwinds as the opioid landscape tightens.

The ADHD portfolio is the growth engine. Jornay PM (delayed-release methylphenidate, taken the night before for morning-symptom control) has no direct equivalent and hit record prescriptions in Q1 2026. AZSTARYS (serdexmethylphenidate / dexmethylphenidate) — the only FDA-approved prodrug of dexmethylphenidate — was acquired from Corium Therapeutics for $650M, closing May 12, 2026, with exclusivity extending to December 2037.

What it's planning

Collegium's strategic agenda through 2026-2027:

• AZSTARYS integration: Expand the salesforce to co-promote both Jornay PM and AZSTARYS to ADHD prescribers. Target $60-70M of AZSTARYS net revenue in H2 2026 and more than $50M run-rate synergies within 12 months.
• ADHD platform consolidation: With combined ADHD revenue potentially approaching $250-265M in FY2026 and sub-2% combined US ADHD market share, the primary growth lever is deepening prescriber penetration in a growing market.
• Deleveraging: Reduce net leverage from approximately 2x adj. EBITDA at the AZSTARYS close to sub-1.5x by mid-2027, funded by $329.3M FY2025 OCF and guided $475-500M FY2026 adj. EBITDA.
• $150M buyback: Authorized through December 31, 2026, pace conditional on deleveraging progress.
• Pain franchise management: Maximize durable cash from Xtampza ER (generic protection to September 2033) and Belbuca while managing the Nucynta IR exclusivity window (potential generic entry as early as January 2027).

Catalysts & demand drivers

Near-term (dated events):

1. AZSTARYS first full-quarter read (Q2 2026, reported approximately August 2026): The most important single data point in the next six months. Tests AZSTARYS supply normalization, salesforce integration, and whether $60-70M H2 2026 revenue is on track — all under a new CCO and CMO.
2. Jornay PM quarterly script data (Q2-Q4 2026): Each IMS/IQVIA release that sustains 12-15%+ YoY growth reinforces the ADHD platform narrative. Full-year 2026 Jornay PM guidance of $190-200M implies approximately $47-50M per quarter vs. $38.9M in Q1 2026 — meaningful acceleration required.
3. $150M buyback execution pace: Management commentary on buyback vs. debt paydown allocation will test conviction in the guidance range.

Structural demand drivers:

• ADHD secular growth: US ADHD drug market estimated at $18.5-26.6B in 2026, growing 5-7% annually. Amphetamine shortage (unresolved as of early 2026) creates prescriber demand for differentiated non-amphetamine options — directly benefiting AZSTARYS and Jornay PM.
• AZSTARYS exclusivity to 2037: 11+ years of branded runway. Collegium paid $650M for a differentiated asset with long exclusivity — the per-year acquisition cost is approximately $55M/year of exclusivity if the asset delivers.
• Pain annuity durability: Xtampza ER with generic protection to September 2033 continues generating cash with limited near-term cliff. Belbuca similarly durable.

Important caveat on third acquisition: The structural BD optionality (additional ADHD/CNS asset post-deleveraging) is unannounced and speculative. It is optionality to hold through the integration period, not a near-term catalyst.

Track record

Revenue (SEC EDGAR XBRL, confirmed):

Note: The revenue CAGR from FY2022 to FY2025 is approximately 19% (not the 26% figure cited in the original bull case, which the verifier flagged as a calculation error). FY2022 includes the Nucynta acquisition effect. The underlying organic trajectory is strong.

Operating income (GAAP, confirmed from EDGAR):

• FY2022: $33.3M
• FY2023: $167.0M
• FY2024: $169.9M
• FY2025: $179.6M

The large jump FY2022→FY2023 reflects the full-year Nucynta contribution. FY2023→FY2025 improvement is modest (+7.5% over two years), as growing ADHD investment and amortization absorb revenue gains.

Net income (GAAP, confirmed):

• FY2022: -$25.0M
• FY2023: $48.2M
• FY2024: $69.2M
• FY2025: $62.9M

Net income declined -9.1% from FY2024 to FY2025 despite +23.6% revenue growth — driven by growing interest expense, amortization of acquired intangibles, and ADHD commercial investment. Post-AZSTARYS, GAAP net income is likely to approach zero or go negative in FY2026 even as adj. EBITDA is record-high.

Operating cash flow (confirmed from EDGAR):

• FY2022: $124.2M
• FY2023: $274.7M
• FY2024: $205.0M
• FY2025: $329.3M

Important: FY2024 saw a significant dip from $274.7M to $205.0M before recovering sharply to $329.3M in FY2025. The FY2025 record is real but the trajectory is not monotonically accelerating.

Cash (confirmed from EDGAR):

• FY2024 end: $70.6M
• FY2025 end: $231.3M
• Note: Post-AZSTARYS (closed May 12, 2026), approximately $350M of cash was deployed. Combined with $300M new delayed-draw term loan proceeds, closing cash was likely approximately $150-180M; the exact figure is not available in the fact sheet (which runs through FY2025 only).

Share count (confirmed from EDGAR):

• End FY2022: 33.8M
• End FY2023: 31.9M
• End FY2024: 31.4M
• End FY2025: 31.7M
• March 31, 2026: 32.4M

Net reduction of 2.1M shares from FY2022 to FY2025 reflects buybacks. However, FY2024→FY2025 saw a slight increase of ~267K shares, and Q1 2026 increased further to 32.4M, suggesting equity compensation dilution is partially offsetting repurchases in the near term.

Valuation

• Price/OCF: $1.03B market cap / $329.3M FY2025 OCF = 3.1x — anomalously low for a company with 19% revenue CAGR over three years and a record OCF year.
• EV/adj. EBITDA (forward): With approximately $1.1B gross debt and approximately $150-180M estimated post-close cash, enterprise value is roughly $1.97-2.0B. Against $475-500M guided FY2026 adj. EBITDA, that is approximately 4.0-4.2x EV/EBITDA — the multiple a declining franchise receives, not a 30%+ ADHD growth platform.
• Consensus target: Sell-side consensus 12-month target approximately $53-54 (research-sourced, 5-6 analysts), implying approximately 68-71% upside at $31.56. Thin coverage (for a company at this OCF scale) amplifies re-rating asymmetry if AZSTARYS delivers.

Fair-value range: $41-55 per share. Method: 4.5x EV/FY2026 guided adj. EBITDA midpoint ($487.5M) yields EV of approximately $2.19B; subtract approximately $1.1B gross debt and add back approximately $165M estimated post-close cash, giving equity value approximately $1.25B or approximately $39-41 per share — conservative case for early integration uncertainty. At 6x EV/EBITDA (standard specialty pharma with durable branded assets and double-digit revenue growth), equity value approaches $53-55 per share, consistent with sell-side consensus. The midpoint is approximately $47-48 (approximately $1.52B equity value). The bear case (4x, flat execution) yields approximately $32-35. Not investment advice.

Ownership & insiders

Institutional ownership dominates (standard for NASDAQ specialty pharma at this scale). Share buybacks since 2021 total $222M+ (research-sourced), with a new $150M authorization through December 2026. Net share count declined from 33.8M (FY2022) to 31.7M (FY2025) — a verified 2.1M share reduction — but the most recent year (FY2024→FY2025) saw a slight increase of approximately 267K shares, and Q1 2026 shows 32.4M, suggesting equity compensation dilution is a near-term offset. Post-AZSTARYS deleveraging priority is likely to constrain buyback pace until leverage reaches sub-1.5x. No active promotion signals detected; share count trend is the opposite of a dilutive pump scheme.

Bull case

COLL trades at approximately 3.1x FY2025 OCF ($329.3M, EDGAR confirmed) and approximately 4.2x FY2026 guided adj. EBITDA midpoint — both anomalously cheap for a company growing revenue at approximately 19% CAGR (FY2022→FY2025, corrected from the 26% figure). The mispricing is structural: COLL is classified as a specialty pharma/opioid company and carries the associated discount, but the cash engine is increasingly funded by ADHD assets growing at 30%+ annually.

Jornay PM delivered $38.9M in Q1 2026 revenue (+36% year-over-year) and crossed 30,000 prescribers at all-time highs (research-sourced, Q1 2026 earnings). Full-year 2026 Jornay guidance: $190-200M (+31% at midpoint). AZSTARYS ($650M acquisition, exclusivity to December 2037) adds a second ADHD asset with $60-70M of H2 2026 revenue guided. In a US ADHD drug market estimated at $18.5-26.6B and growing 5-7% annually, combined ADHD share is sub-2% — structural headroom is large.

The pain portfolio is not collapsing: Xtampza ER grew +7% to $50.8M in Q1 2026 and Belbuca +2% to $52.6M, with generic protection to September 2033 and approximately 2029 respectively (research-sourced). The pain segment is a durable annuity funding ADHD investment, not a melting ice cube.

The valuation unlock: if Q2 2026 AZSTARYS revenues track to guidance and Jornay PM sustains trajectory, the market re-classifies COLL from "opioid company" to "ADHD platform with a pain annuity" — a classification shift the combined revenue mix will support by Q3 2026. At even a modest 5x EV/EBITDA re-rating, equity value approaches $47-50 per share from $31.56 today.

Bear case & red flags

1. Net income declining despite surging revenue. Revenue grew +23.6% from FY2024 to FY2025 (from $631.4M in 2024 to $780.6M in 2025, EDGAR confirmed). Net income declined -9.1% (from $69.2M in 2024 to $62.9M in 2025, EDGAR confirmed). Operating income improved only $9.7M (+5.7%) from $169.9M to $179.6M. The OCF / operating income gap of $149.7M ($329.3M - $179.6M) is largely non-cash amortization of acquired drug intangibles — real economic cost (the patent lives of Nucynta, Jornay PM, and other acquired assets are being consumed). Post-AZSTARYS, this dynamic accelerates: the new intangible stack from a $650M acquisition will add further amortization, and GAAP net income is likely to go negative in FY2026 even as adj. EBITDA is record-high. Severity: Medium. Investors anchored to OCF see strength; investors anchored to earnings quality see an intangibles-consuming machine.

2. Nucynta IR generic entry as early as 2027. Per patent watch databases, Nucynta IR generic entry is estimated as early as January 2027 (research-sourced; not in EDGAR fact sheet — warrants direct verification against USPTO/ANDA filings). In Q1 2026, the Nucynta franchise contributed $47.0M total (research-sourced). Loss of Nucynta IR exclusivity — with typical generic volume capture of 60-70% in 12-18 months post-launch — could compress the pain segment by $25-40M annually. Management's FY2026 guidance of $865-895M has not visibly isolated the Nucynta IR erosion impact, making the guidance harder to model precisely. Severity: High.

3. CCO and CMO departed at the worst moment. Both the Chief Commercial Officer and Chief Medical Officer are departing following the AZSTARYS acquisition close (May 12, 2026). These are the two roles most responsible for executing AZSTARYS commercial launch integration into the Jornay PM salesforce, managing prescriber relationships, and delivering the $60-70M H2 2026 AZSTARYS revenue target. Specialty pharma salesforce integrations without commercial leadership continuity routinely take 2-3 quarters longer than projected. If AZSTARYS H2 2026 revenue comes in at $35-45M instead of $60-70M, and the miss coincides with early Nucynta IR generic pressure, FY2026 guidance could be threatened from two directions simultaneously. Severity: High.

4. Leverage jump from sub-1x to approximately 2x net debt/EBITDA. Post-AZSTARYS gross debt rose to approximately $1.1B ($564.3M senior secured notes + $238.5M convertible notes + $300M delayed draw term loan — debt figures research-sourced, not confirmable from the provided EDGAR fact sheet). FY2025 year-end cash was $231.3M (EDGAR confirmed), with approximately $350M deployed in the deal, leaving approximately $150-180M post-close cash. At the floating component of approximately SOFR+325 bps (approximately 7.6-8% all-in), the incremental $300M term loan costs approximately $23-24M/year in interest. Combined with existing debt service, FY2026 interest expense will materially compress GAAP net income — likely toward zero or negative. Severity: Medium-High.

5. AZSTARYS supply constraints in early 2026. Independent pharmacy availability data documents AZSTARYS availability friction in early 2026, with availability issues reported before Collegium's ownership. If supply/formulary gaps persist into Q2-Q3 2026 under new commercial leadership, the $60-70M H2 2026 revenue target faces compounding headwinds. Source: medfinder.com blog post (research-sourced). Severity: Medium.

6. Share count not declining in the most recent period. FY2024 year-end share count was 31,440,155 (EDGAR confirmed). FY2025 year-end was 31,707,608 (EDGAR confirmed) — an increase of approximately 267,000 shares. Q1 2026 shows 32,406,969 shares (EDGAR confirmed) — a further increase. Equity compensation dilution is outpacing buybacks in the near term. Post-AZSTARYS, with debt deleveraging the stated priority over buybacks, the per-share accretion thesis from the $150M buyback authorization is likely deferred to 2027 at the earliest. Severity: Low-Medium.

7. Opioid regulatory and litigation tail — unquantified. State AG investigations (Washington, New Hampshire, Maryland, Massachusetts) into opioid sales and marketing remain open. The prior settlement of 27 lawsuits was $2.75M — historically small — but state AG investigations operate on different timelines and are not capped by prior private settlements. No accrual or estimated liability range is disclosed. This is a known-unknown overhang. Severity: Medium (reputational, not modeled cash flow risk).

8. OCF trajectory is not monotonic. The FY2025 record OCF of $329.3M followed a significant dip to $205.0M in FY2024 from $274.7M in FY2023 (all EDGAR confirmed). FY2025 was a record, but the sequence is not a straight line up. Investors should not treat $329M as a floor.

No gate flags triggered. OCF strongly positive ($329.3M FY2025), no going-concern language, no active promotion signals, no reverse split, no auditor or material weakness disclosures, no preferred-over-common liquidation preference.

Interesting findings

• The revenue CAGR figure from FY2022 to FY2025 was cited as 26% in the original bull analysis. The correct figure — calculated from confirmed EDGAR data (FY2022 base of $463.9M, FY2025 end of $780.6M, 3-year span) — is approximately 19%. The verifier flagged this; the error does not change the qualitative investment thesis but is material for modeling.
• FY2024 OCF of $205.0M was a significant year-over-year dip from $274.7M in FY2023 before the FY2025 recovery to $329.3M. This non-monotonic trajectory is the fact sheet's most important context for evaluating OCF claims.
• The $149.7M gap between FY2025 OCF ($329.3M) and GAAP operating income ($179.6M) is primarily amortization of acquired drug intangibles — a real economic cost representing consumption of the patent lives of Nucynta, Jornay PM, and other acquired franchises. Post-AZSTARYS ($650M deal), this amortization load grows further, likely suppressing GAAP net income toward zero or below in FY2026.
• No promotion signals detected across the entire research sweep. The Paris Hilton "Embrace Your Sparkle" ADHD awareness campaign is standard branded pharmaceutical DTC/advocacy marketing, not investor promotion. Share count trend (net reduction over 2022-2025) is the opposite of the dilutive issuance pattern common in pump schemes.
• AZSTARYS exclusivity runs to December 2037 — 11.6 years from the May 2026 close. At a $650M acquisition price, the implied per-year exclusivity cost is approximately $56M/year, manageable if the asset delivers $100M+ in annual revenue at maturity.
• The INTRA-CELLULAR (ITCI) comparison included in the original peer analysis is not directly useful — ITCI was acquired by J&J in 2025. The most useful public comps are Supernus Pharmaceuticals (SUPN, approximately $2.9B market cap, broader CNS) and Assertio Holdings (ASRT, approximately $116.5M market cap, specialty pain, being acquired by Zydus Lifesciences), both research-sourced.

The read

Collegium is a genuinely cash-generative specialty pharma executing a credible pivot from a declining-franchise cash cow (branded opioids) to a growing-franchise platform (ADHD). The numbers support the pivot: FY2025 OCF of $329.3M on $780.6M revenue is exceptional, and Jornay PM's prescription momentum — 206,000+ quarterly scripts, 30,000 prescribers, 36% revenue growth in Q1 2026 — is verifiable. The AZSTARYS acquisition adds a second ADHD asset with 11+ years of exclusivity at a multiple that is defensible if the asset delivers.

The market is pricing COLL as a declining opioid company (approximately 4x EV/EBITDA on 2026 guidance). The reality — if AZSTARYS integration executes — is a cash-generative ADHD platform company with a pain annuity, temporarily levered at approximately 2x post-acquisition and de-levering fast. That description gap is where the return lives.

The bear case is not about near-term solvency. It is about three compounding execution risks arriving in the same 18-month window: (1) AZSTARYS commercial integration under a new CCO and CMO, (2) Nucynta IR potential generic entry as early as January 2027, and (3) AZSTARYS supply normalization needed before the salesforce can even fully drive the asset. Any one of these is manageable; all three simultaneously is the scenario that extends the market's rerating delay by 2-4 quarters.

The thesis break condition: if Q2 2026 AZSTARYS revenue comes in below $30M (implying supply or adoption failure) or if Jornay PM script growth decelerates below 8% year-over-year in the same period, both visible in the data, reassessment is warranted. The base case — AZSTARYS integrates reasonably well in 2-3 quarters, Jornay sustains trajectory, leverage de-levers — supports approximately $41-55 fair value vs. $31.56 current.

Research, not investment advice. Figures sourced from SEC filings and public data; verify before acting.